Rocket Pharma has won FDA approval for the first gene therapy for LAD-I, a devastating genetic disorder causing severe vulnerability to infections.

AstraZeneca’s investigational antibody for chronic obstructive pulmonary disease has succeeded in two late-stage studies, despite having previously failed in a mid-stage trial. And, unexpectedly, the

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy

Senior HHS official and head of Medicare Chris Klomp didn’t mince words when he called competition with China’s ascending biotech industry “a war.” Klomp’s comments,

Biopharma industry representatives are taking issue with some of the FDA’s more political proposals in the next round of user fee agreements, particularly ones that